Biopharmaceuticals Contract Manufacturing Market Report 2025-2035

The Biopharmaceuticals Contract Manufacturing Market Report 2025-2035 (Including Impact of U.S. Trade Tariffs): This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Biopharmaceutical contract manufacturing has become a critical enabler for companies navigating the complexity of biologics and advanced therapies. With rising demand for monoclonal antibodies, cell therapies, and gene therapies, outsourcing provides biopharma innovators with access to scalable, regulatory-compliant infrastructure while allowing them to concentrate resources on discovery and development. Contract manufacturing organisations (CMOs) play a pivotal role in reducing time-to-market, optimising costs, and offering technical expertise that many firms cannot replicate in-house.

The sector is experiencing strong growth, propelled by the expanding pipeline of therapies addressing oncology, rare diseases, and autoimmune conditions. Biosimilars are also a key driver, as patent expirations on blockbuster biologics fuel a wave of development and manufacturing partnerships. Both emerging biotech firms and global pharmaceutical leaders are increasingly turning to CMOs to achieve greater operational agility and capital efficiency. The COVID-19 pandemic further highlighted the importance of resilient, high-capacity networks, cementing CMOs as indispensable partners in global healthcare preparedness.

Technological advances, ranging from AI-driven process optimisation to continuous bioprocessing, are transforming efficiency and quality standards in outsourced production. At the same time, emerging markets such as India and China are becoming more integral to global supply chains, supported by cost competitiveness and improving regulatory frameworks. These dynamics are expanding the geographic footprint of contract manufacturing, diversifying risk, and opening new avenues for growth.

As demand for biologics and next-generation therapies accelerates, contract manufacturing will remain a cornerstone of the biopharmaceutical value chain. CMOs are evolving from capacity providers into strategic partners, offering innovation, resilience, and flexibility that are increasingly essential in a competitive and fast-changing global healthcare landscape.

What would be the Impact of US Trade Tariffs on the Global Biopharmaceuticals Contract Manufacturing Market?

The introduction of U.S. trade tariffs on pharmaceutical inputs, biologics, and specialised manufacturing equipment is creating new pressures for the global biopharmaceutical contract manufacturing market. By raising the cost of raw materials, reagents, and critical production tools, these measures are disrupting established cost structures and supply chains. Contract manufacturers that rely on cross-border sourcing or export to the United States are particularly exposed, facing higher operating costs, potential delays, and reduced margins–factors that could translate into increased pricing for sponsors and limit the affordability of biologics and biosimilars.

At the same time, tariffs are prompting a reassessment of global outsourcing strategies. Biopharmaceutical companies are moving to diversify suppliers, invest in localised production capacity, and channel outsourcing toward regions unaffected by tariffs. This shift is increasing interest in Southeast Asia, India, and selected European markets, where improving regulatory standards and competitive cost bases support expansion. While U.S.-based CMOs may benefit in the short term from stronger domestic demand, their ability to maintain this position will depend on policy clarity and the scale of infrastructure investment.

In effect, tariffs are acting as both a disruptor and a catalyst–raising immediate costs while driving structural changes in how and where manufacturing is conducted. For CMOs and their partners, the priority will be to adapt quickly, balancing short-term challenges with the longer-term opportunity to build more resilient and regionally diversified supply networks.

What Questions Should You Ask before Buying a Market Research Report?

• How is the biopharmaceuticals contract manufacturing market evolving?
• What is driving and restraining the biopharmaceuticals contract manufacturing market?
• How will each biopharmaceuticals contract manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
• How will the market shares for each biopharmaceuticals contract manufacturing submarket develop from 2025 to 2035?
• What will be the main driver for the overall market from 2025 to 2035?
• Will leading biopharmaceuticals contract manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
• Who are the leading players and what are their prospects over the forecast period?
• What are the biopharmaceuticals contract manufacturing projects for these leading companies?
• How will the industry evolve during the period between 2025 and 2035? What are the implications of
  biopharmaceuticals contract manufacturing projects taking place now and over the next 10 years?


• Is there a greater need for product commercialisation to further scale the biopharmaceuticals contract manufacturing market?
• Where is the biopharmaceuticals contract manufacturing market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Biopharmaceuticals Contract Manufacturing market today, and over the next 10 years:

• Our 393-page report provides 138 tables and 174 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

Forecasts to 2035 and other analyses reveal commercial prospects

• In addition to revenue forecasting to 2035, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.

Segments Covered in the Report

Source

• Mammalian
• Non-mammalian

Service

• Process Development
  - Downstream
  
  - Upstream


• Fill & Finish Operations
• Analytical & QC Studies
• Packaging

Product

• Biologics
  - Monoclonal Antibodies (mAbs)
  
  - Recombinant Proteins
  
  - Vaccines
  
  - Others


• Biosimilars

Company Size

• Small
• Mid-sized
• Large

Scale of Operations

• Preclinical
• Clinical
• Commercial

Therapeutic Area

• Oncology
• Autoimmune Diseases
• Cardiovascular Diseases
• Metabolic Diseases
• Infectious Diseases
• Neurology
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 26 leading national markets:

North America

• U.S.
• Canada

Europe

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

MEA

• GCC
• South Africa
• Rest of MEA

The report also includes profiles for some of the leading companies in the Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035, with a focus on this segment of these companies' operations.

Leading companies and the potential for market growth

• AbbVie Inc.
• AGC Biologics
• Avantor, Inc.
• Binex Co., Ltd.
• Boehringer Ingelheim International GmbH
• Cambrex Corporation
• Catalent, Inc
• Curia Global, Inc.
• Cytiva
• FUJIFILM Diosynth Biotechnologies
• JRS PHARMA
• Jubilant Pharma Limited
• KBI Biopharma
• Lonza
• Pfizer CentreOne
• ProBioGen AG
• Rentschler Biopharma SE
• Samsung Biologics
• Sandoz Group AG
• TOYOBO CO., LTD.
• Thermo Fisher Scientific Inc.
• WuXi Biologics

Overall world revenue for Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035 in terms of value the market will surpass US$17.0 billion in 2025, our work calculates. We predict strong revenue growth through to 2035. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035 report help you?

In summary, our 390+ page report provides you with the following knowledge:

• Revenue forecasts to 2035 for Biopharmaceuticals Contract Manufacturing Market 2025 to 2035, with forecasts for source, service, product, company size, and scale of operations, each forecast at a global and regional level – discover the industry's prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2035 for five regional and 26 key national markets – See forecasts for the Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 22 of the major companies involved in the Biopharmaceuticals Contract Manufacturing Market, 2025 to 2035.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment. Show more